Bill SponsorBILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 5632
116th Congress(2019-2020)
FDA Accountability for Public Safety Act
Introduced
Introduced
Introduced in House on Jan 16, 2020
Overview
Text
Introduced in House 
Jan 16, 2020
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in House(Jan 16, 2020)
Jan 16, 2020
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
H. R. 5632 (Introduced-in-House)


116th CONGRESS
2d Session
H. R. 5632


To establish procedures regarding the approval of opioid drugs by the Food and Drug Administration.

IN THE HOUSE OF REPRESENTATIVES

January 16, 2020

Mr. Kim introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To establish procedures regarding the approval of opioid drugs by the Food and Drug Administration.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “FDA Accountability for Public Safety Act”.

SEC. 2. Approval against the recommendation of the FDA advisory committee on opioid drugs.

(a) In General.—Any approval of an application or supplement to an application under section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) for a drug that is an opioid against the recommendation of the advisory committee pursuant to section 106 of the Comprehensive Drug and Recovery Act of 2016 (Public Law 114–198) shall be made by the Commissioner of Food and Drugs (referred to in this section as the “Commissioner”) and shall not be delegated.

(b) Reports to Congress.—If the Commissioner approves a drug as described in subsection (a), the Commissioner shall—

(1) submit a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, and to any member of Congress that requests the report, that includes—

(A) medical and scientific evidence regarding patient safety that clearly supports the Commissioner's decision to approve the opioid drug against the recommendation of the advisory committee; and

(B) a disclosure of any potential conflicts of interest that may exist regarding any official of the Food and Drug Administration who was involved in the decision to approve the drug prior to the Commissioner's final decision under subsection (a); and

(2) at the request of the Committee on Health, Education, Labor, and Pensions of the Senate or the Committee on Energy and Commerce of the House of Representatives, testify before that committee regarding the Commissioner's decision to approve the opioid drug against the recommendation of the advisory committee.

(c) Prohibition on marketing.—A drug approved as described in subsection (a) shall not be introduced or delivered for introduction into interstate commerce until the report described in subsection (b)(1) has been submitted to Congress.

(d) Scope of advisory committee review.—Section 106(a)(1)(A) of the Comprehensive Addiction and Recovery Act of 2016 (Public Law 114–198) is amended—

(1) by inserting “, or supplement to an application,” after “application” each place such term appears; and

(2) by striking “of a new” and inserting “for”.